A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis.
Forty-seven climbers participated in a double-blind, randomized trial comparing acetazolamide 250 mg, dexamethasone 4 mg, and placebo every eight hours as prophylaxis for acute mountain sickness during rapid, active ascent of Mount Rainier (elevation 4,392 m). Forty-two subjects (89.4 percent) achieved the summit in an average of 34.5 hours after leaving sea level. At the summit or high point attained above base camp, the group taking dexamethasone reported less headache, tiredness, dizziness, nausea, clumsiness, and a greater sense of feeling refreshed (p less than or equal to 0.05). In addition, they reported fewer problems of runny nose and feeling cold, symptoms unrelated to acute mountain sickness. The acetazolamide group differed significantly (p less than or equal to 0.05) from other groups at low elevations (1,300 to 1,600 m), in that they experienced more feelings of nausea and tiredness, and they were less refreshed. These drug side effects probably obscured the previously established prophylactic effects of acetazolamide for acute mountain sickness. Separate analysis of an acetazolamide subgroup that did not experience side effects at low elevations revealed a prophylactic effect of acetazolamide similar in magnitude to the dexamethasone effect but lacking the euphoric effects of dexamethasone. This study demonstrates that prophylaxis with dexamethasone can reduce the symptoms associated with acute mountain sickness during active ascent and that acetazolamide can cause side effects that may limit its effectiveness as prophylaxis against the disease.
Ellsworth
A J
AJ
School of Pharmacy, University of Washington, Seattle 98195.
Larson
E B
EB
Strickland
D
D
D000086:Acetazolamide / Q000009:adverse effects / Q000627:therapeutic use*; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000532:Altitude Sickness / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009051:Mountaineering; D011897:Random Allocation; D012720:Severity of Illness Index
D003907:Dexamethasone; D000086:Acetazolamide